KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Neoadjuvant treatment in resectable pancreatic cancer: Why is upfront surgery so hard to be beaten?

Pedro Luiz Serrano Uson Junior, Kunal C Kadakia, Raphael L C Araujo

World J Clin Oncol 16(9) 108955

PMID41024839
PMCIDPMC12476613
DOI10.5306/wjco.v16.i9.108955
发表日期2025-09-30
摘要

摘要

Neoadjuvant treatment is being extensively evaluated in pancreatic ductal adenocarcinoma (PDAC). This interest is appropriate given the dismal long-term prognosis for most patients who undergo upfront surgery. Despite prospective, retrospective and randomized trials supporting the role of neoadjuvant therapy in general for PDAC, the long-term benefit specifically for patients with resectable PDAC remains unclear. The phase III PREOPANC trial showed an improvement in overall survival in borderline resectable PDAC with neoadjuvant gemcitabine-based chemoradiation compared to upfront surgery alone, however, no such benefit was observed in the resectable cohort. Notably, three randomized trials (PANACHE01-PRODIGE 48, NORPACT-1, and PREOPANC-2) failed to show a clear improvement in overall survival with a neoadjuvant approach. The ongoing NeoFOL-R, PREOPANC-3, and the Alliance A021806 will help clarify the role of neoadjuvant therapy in resectable PDAC. In this minireview article we summarize the data surrounding neoadjuvant therapy in resectable pancreatic cancer and discuss future considerations of trials in this subgroup.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。